EMERALD Ph III Study in discussion w/ Dr. Aditya Bardia (now FDA Approved)

Discussing the EMERALD Phase III study which resulted in the FDA approval of the first oral selective estrogen receptor degrader (SERD) after demonstrating statistically significant and clinically meaningful benefit in postmenopausal women and men, with ER+, HER2- metastatic breast cancer patients, post progression in first line with endocrine therapy and CDK4/6i. In discussion with the lead author, Dr. Aditya Bardia - Associate Professor at Massachusetts General Hospital - Harvard Medical School.   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at [email protected]